OBJECTIVE: Eradication of H. pylori is an important treatment strategy in peptic ulcer patients. Current regimens of eradication consist of proton pump inhibitor (PPI) and two antibiotics. Effects of PPI may depend on their metabolism, and other factors important for the pathophysiology of peptic ulcer disease. Aim of the present study was to evaluate an association of CYP2C19, MDR1, and IL-1B polymorphisms with the eradication rate of H. pylori in Polish Caucasian patients treated with a triple therapy of pantoprazole, amoxicillin, and metronidazole. METHODS: A total of 139 peptic ulcer patients, positive for H. pylori infection, were treated with triple therapy (pantoprazole + amoxicillin + metronidazole). Subsequently, the patients were divided into two groups (group 1, success, and group 2, failure of eradication after therapy) and genotyped by the PCR-RFLP method for the presence of CYP2C19 variant alleles (*2, *3, and *17), and MDR1 3435C>T and IL-1B +3954C>T polymorphisms. Pantoprazole serum concentrations were measured using the HPLC method. RESULTS: No significant differences in frequency or distribution of CYP2C19 genotypes were found between the two groups of patients (i.e., with successful H. pylori eradication and treatment failure). However, any carrier of defective CYP2C19*2/*2 genotype was found among patients with treatment failure. Similarly, MDR1 and IL-1B genotypes were found to be significantly associated with the success or failure of H. pylori eradication. Univariate and multivariate analysis of the genotypes did not reveal any significant association between the genotypes and H. pylori eradication. Pantoprazole concentrations differed significantly, and were the highest in patients with defective allele CYP2C19*2 carriers and lowest in hyperactive genotype homozygotes CYP2C19*17/*17. CONCLUSION: The results suggest that the CYP2C19 genotype contrary to MDR1 and IL-1B genotypes may have an impact on the efficacy of H. pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole.
OBJECTIVE: Eradication of H. pylori is an important treatment strategy in peptic ulcerpatients. Current regimens of eradication consist of proton pump inhibitor (PPI) and two antibiotics. Effects of PPI may depend on their metabolism, and other factors important for the pathophysiology of peptic ulcer disease. Aim of the present study was to evaluate an association of CYP2C19, MDR1, and IL-1B polymorphisms with the eradication rate of H. pylori in Polish Caucasian patients treated with a triple therapy of pantoprazole, amoxicillin, and metronidazole. METHODS: A total of 139 peptic ulcerpatients, positive for H. pyloriinfection, were treated with triple therapy (pantoprazole + amoxicillin + metronidazole). Subsequently, the patients were divided into two groups (group 1, success, and group 2, failure of eradication after therapy) and genotyped by the PCR-RFLP method for the presence of CYP2C19 variant alleles (*2, *3, and *17), and MDR1 3435C>T and IL-1B +3954C>T polymorphisms. Pantoprazole serum concentrations were measured using the HPLC method. RESULTS: No significant differences in frequency or distribution of CYP2C19 genotypes were found between the two groups of patients (i.e., with successful H. pylori eradication and treatment failure). However, any carrier of defective CYP2C19*2/*2 genotype was found among patients with treatment failure. Similarly, MDR1 and IL-1B genotypes were found to be significantly associated with the success or failure of H. pylori eradication. Univariate and multivariate analysis of the genotypes did not reveal any significant association between the genotypes and H. pylori eradication. Pantoprazole concentrations differed significantly, and were the highest in patients with defective allele CYP2C19*2 carriers and lowest in hyperactive genotype homozygotes CYP2C19*17/*17. CONCLUSION: The results suggest that the CYP2C19 genotype contrary to MDR1 and IL-1B genotypes may have an impact on the efficacy of H. pylori eradication in peptic ulcerpatients treated with pantoprazole in Polish Caucasian peptic ulcerpatients administered pantoprazole, amoxicillin, and metronidazole.
Authors: Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg Journal: Clin Pharmacol Ther Date: 2006-01 Impact factor: 6.875
Authors: Barbara Gawrońska-Szklarz; Joanna Wrześniewska; Teresa Starzyńska; Andrzej Pawlik; Krzysztof Safranow; Katarzyna Ferenc; Marek Droździk Journal: Eur J Clin Pharmacol Date: 2005-06-23 Impact factor: 2.953
Authors: T Furuta; M Sugimoto; N Shirai; F Matsushita; H Nakajima; J Kumagai; K Senoo; C Kodaira; M Nishino; M Yamade; M Ikuma; H Watanabe; K Umemura; T Ishizaki; A Hishida Journal: Aliment Pharmacol Ther Date: 2007-09-01 Impact factor: 8.171
Authors: Stuart A Scott; Katrin Sangkuhl; Alan R Shuldiner; Jean-Sébastien Hulot; Caroline F Thorn; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2012-02 Impact factor: 2.089
Authors: Rasmus S Pedersen; Charlotte Brasch-Andersen; Sarah C Sim; Troels K Bergmann; Jónrit Halling; Maria S Petersen; Pál Weihe; Hege Edvardsen; Vessela N Kristensen; Kim Brøsen; Magnus Ingelman-Sundberg Journal: Eur J Clin Pharmacol Date: 2010-07-28 Impact factor: 2.953
Authors: Shailja C Shah; Adam Tepler; Cecilia P Chung; Giovanni Suarez; Richard M Peek; Adriana Hung; Christianne Roumie; Neeraj Narula Journal: Gastroenterology Date: 2021-08-03 Impact factor: 22.682